×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Why You Shouldn't Bet Against AnaptysBio (ANAB) Stock.
Yahoo Finance
AnaptysBio (ANAB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
3 weeks ago
AnaptysBio's skin disease drug meets main goal in late-stage study
Reuters
AnaptysBio Inc said on Monday its experimental drug to treat a type of rare skin disease met the main goal in a late-stage study.
6 months ago
AnaptysBio (NASDAQ:ANAB) Stock Price Up 8.2%
MarketBeat
AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report)'s share price rose 8.2% on Friday . The stock traded as high as $20.52 and last traded at...
2 days ago
Skin Disease-Focused AnaptysBio Earns Analyst Upgrade On Positive Outlook For Clinical Triggers
markets.businessinsider.com
Monday, AnaptysBio Inc (NASDAQ:ANAB) reported a fourth-quarter 2023 EPS of $(1.59), slightly better than the consensus of $(1.60). ...
1 month ago
AnaptysBio Touts Positive Top-Line Phase III Data for Pustular Psoriasis Candidate
BioSpace
The company's experimental lgG4 antibody met the primary endpoint in a late-stage study of the rare skin disease. AnaptysBio will submit an...
6 months ago
Trade Alert: President Of AnaptysBio Daniel Faga Has Sold Stock
Simply Wall Street
Trade Alert: President Of AnaptysBio Daniel Faga Has Sold Stock ... Some AnaptysBio, Inc. (NASDAQ:ANAB) shareholders may be a little concerned to...
1 month ago
Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week
MSN
Many stocks were wobbly over the past few trading days, but we can't say that about biotech AnaptysBio (NASDAQ: ANAB). The company's shares closed the week...
2 weeks ago
AnaptysBio announces top-line data showing rapid clearance of generalized pustular psoriasis (GPP), a rare systemic ...
Fierce Biotech
New top-line data from a global Phase 3 clinical trial of patients with generalized pustular psoriasis (GPP) flares show rapid clearance of...
6 months ago
AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy?
Yahoo Finance
AnaptysBio, Inc. (ANAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
2 months ago
AnaptysBio draws a bead on Bayer's Spevigo after phase 3 win
Pharmaphorum
AnaptysBio draws a bead on Bayer's Spevigo after phase 3 win. News. After disappointing results in other indications, AnaptysBio has a route to...
6 months ago